Uptake of Estramustine in Malignant Brain Tumours
Author Information
Author(s): A.T. Bergenheim, P.O. Gunnarsson, K. Edman, E. von Schoultz, M.I. Hariz, R. Henriksson
Primary Institution: University Hospital, Umeå, Sweden
Hypothesis
The uptake and retention of estramustine phosphate (EMP) in malignant brain tumours is influenced by the presence of estramustine binding protein (EMBP).
Conclusion
The study found high concentrations of estramustine metabolites in brain tumour tissue, suggesting potential therapeutic effects of EMP in treating malignant brain tumours.
Supporting Evidence
- High concentrations of estramustine metabolites were found in brain tumour tissue.
- Patients with antacid treatment had lower drug uptake.
- Immunohistochemical staining showed high EMBP presence in most tumours.
Takeaway
This study shows that a cancer drug called estramustine can get into brain tumours, which might help treat them better.
Methodology
Sixteen patients with malignant brain tumours were given estramustine phosphate before surgery, and tissue samples were analyzed for drug metabolites and EMBP presence.
Limitations
The study had a small sample size and variability in drug absorption among patients.
Participant Demographics
Mean age of participants was 56.1 years, with a male/female ratio of 9/7.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website